ELMD$23.7
$23.6125
Chart
Performance
Key Stats
AI ELMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyElectromed, Inc. (ELMD) presents a mixed but generally positive investment profile. Fundamentally, the company shows solid growth and improving profitability, supported by a strong balance sheet. Thematic exposure to healthcare innovation is a positive, although current technical indicators suggest some short-term caution. Overall, it's a promising company for growth-oriented investors with a long-term horizon.
Thematic
Electromed operates in the healthcare technology sector, specifically focusing on respiratory therapy. Its products address significant medical needs, offering potential growth from an aging population and increased prevalence of respiratory conditions.
Fundamental
Electromed demonstrates solid financial health with consistent revenue growth and improving profitability. The company maintains a strong balance sheet with manageable debt and positive cash flow generation.
Technical
Electromed's stock is trading near its 52-week low and exhibits mixed technical signals. While some short-term indicators are leaning positive, the overall trend and key moving averages suggest a neutral to cautious outlook.
| Factor | Score |
|---|---|
| Healthcare Innovation | 85 |
| Demographic Trends | 80 |
| Market Penetration | 65 |
| Regulatory Landscape | 75 |
| Competition | 55 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 75 |
| Growth | 70 |
| Balance Sheet Health | 85 |
| Cash Flow | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 55 |
| Support & Resistance | 60 |
| Short-Term Indicators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
The company has shown a consistent trend of beating EPS estimates in recent quarters, with a notable surprise of 433.33% in Q4 2024, indicating strong operational execution and forecasting accuracy.
Improving Net Margins
Net margin has shown a positive trend, increasing from 5.5% in Q2 2022 to 12.3% in Q2 2024, suggesting effective cost management and improved profitability on sales.
Bearish Points (8)
High Quarterly P/E Ratios
Recent quarterly P/E ratios are significantly high (e.g., 105.8 in Q1 2025), suggesting that the stock may be overvalued based on current earnings relative to short-term performance.
Significant Short-Term Performance Decline
The stock has experienced a substantial decline of -43.21% over the last 6 months and -37.48% year-to-date, indicating significant negative market sentiment or headwinds.
Calendar
August 2025
25
Next Earnings Date
H: $
A: $
L: $
H: 16.61M
A: 16.51M
L: 16.40M
Profile
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Seasonals
Price Target
32.00 USD
The 39 analysts offering 1 year price forecasts for ELMD have a max estimate of 38.00 and a min estimate of 29.00.
Financial Position Analysis
Ownership
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Leading global developer, manufacturer, and distributor of medical devices for treating and managing sleep apnea, COPD, and other respiratory conditions. Direct competitor in respiratory care.
Weight: 95
Major diversified health technology company with a significant presence in respiratory care and sleep solutions, including ventilators and CPAP devices (despite recent recalls).
Weight: 93
Acquired Hill-Rom, integrating 'The Vest' airway clearance system, making them a direct competitor to ELMD in high-frequency chest wall oscillation.
Weight: 90
A leading provider of home medical equipment (HME), including respiratory therapy equipment such as oxygen concentrators, CPAP devices, and ventilators, directly serving patients with pulmonary needs.